lenalidomide,tafasitamab
morphosys,incyte
['dlbcl', 'l-mind', 'morphosys']
at #aacr23, we presented new five-year data from our phase 2 l-mind study in relapsed or refractory #dlbcl. read more: 
Global commercial-stage biopharmaceutical company driven by our mission: More life for people with cancer. https://t.co/IMbjQ1Ym1Z